SCHEMBL17599524

SCHEMBL17599524

Cc1cc(C)c(C)c(S(=O)(=O)Nc2cc(C3CCCC3C(=O)O)cc3ccccc23)c1C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.49
▸ KMT2A Q03164 5/20 0.49
▸ KDM4E B2RXH2 4/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ HPGD P15428 3/20 0.49
▸ HSD17B10 Q99714 3/20 0.49
▸ CRHBP P24387 1/20 0.49
▸ CRHR2 Q13324 1/20 0.49
▸ KEAP1 Q14145 7/20 0.48
▸ NFE2L2 Q16236 4/20 0.48
▸ GAA P10253 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599544 0.90 KDM4E (0.45) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599564 0.83 MEN1 (0.44) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599414 0.82 KEAP1 (0.56) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599450 0.74 KEAP1 (0.66) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599530 0.73 KEAP1 (0.73) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599481 0.72 KEAP1 (0.50) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17614106 0.72 KEAP1 (0.50) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599540 0.72 KEAP1 (0.50) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599535 0.72 KDM4E (0.53) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599538 0.72 KDM4E (0.53) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998292-A1 Naphthyl sulfonamide derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP claimed
EP-2998292-A1 Naphthyl sulfonamide derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
EP-2998292-A1 Naphthyl sulfonamide derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback